Body Composition, Relative Dose Intensity, and Adverse Events among Patients with Colon Cancer

Area of Science:

• Oncology
• Radiology
• Body Composition Analysis

Background:

• Standard chemotherapy dosing relies on body surface area, potentially overlooking body composition.
• Low muscle mass is linked to increased chemotoxicity risk.
• Current dosing strategies may not optimize treatment for all colon cancer patients.

Purpose of the Study:

• To investigate the association between body composition (muscle and adipose tissue) and chemotherapy outcomes in colon cancer patients.
• To determine if body composition metrics can predict relative dose intensity (RDI) and adverse events.
• To explore personalized dosing strategies based on body composition.

Main Methods:

• Assessed skeletal muscle area (SMA) and total adipose tissue (TAT) using CT scans.
• Measured appendicular lean mass (ALM) and total body fat (TBF) using DXA.
• Quantified total body skeletal muscle mass via D3-creatine (D3Cr) dilution.
• Analyzed associations with reduced RDI (<85%) and adverse events using logistic regression and generalized estimating equations.

Main Results:

• Higher CT SMA and DXA ALM were significantly associated with a lower risk of reduced RDI (ORs: 0.56).
• No significant associations were found between muscle or adipose tissue measurements and adverse events.
• Skeletal muscle mass, assessed by CT and DXA, predicted chemotherapy dose intensity.

Conclusions:

• Increased muscle mass is associated with improved chemotherapy completion in colon cancer patients.
• Body composition, specifically muscle mass, may be a crucial factor in chemotherapy outcomes.
• Personalizing chemotherapy dosing based on body composition could enhance treatment efficacy and patient outcomes.